Phase 2CompletedAge-related condition
Phase 2 Study With Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye
A Phase 2, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of 1.0% and 2.5% Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye
- Sponsor
- Herantis Pharma Plc. (Industry)
- Enrolment
- 161 enrolled
- Conditions
- Dry Eye Syndrome
- Interventions
- cis-UCA ophthalmic solution 1.0%; cis-UCA ophthalmic solution 2.5%; Placebo ophthalmic solution
- Ages
- adults, older adults
- Registry
- NCT02326090
Full record on ClinicalTrials.gov
From the registry
The objective of the Phase 2 study is to compare the safety and efficacy of cis-UCA Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.
Primary outcomes
- Corneal Fluorescein Staining
- Symptom Score
History
Last registry update
Primary completion
Registered
Started